ArticleAnnals of medicine and surgery (2012)2025
Atypical presentation of hepatitis E with extremely elevated bilirubin levels: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Hepatitis E virus (HEV) infection is usually self-limiting, with mild to moderate liver enzyme and bilirubin elevations. However, extreme hyperbilirubinemia is uncommon and may resemble more severe hepatic pathologies. This case highlights an atypical HEV presentation with alarmingly high bilirubin levels in a healthy adult. Case presentation: A 34-year-old male textile worker with no prior liver disease presented with a 5-day history of vomiting, jaundice, and lethargy. Initial laboratory results showed total bilirubin of 22.8 mg/dL (direct: 16.1 mg/dL), alanine transaminase (ALT) of 2590 U/L, and lactate dehydrogenase (LDH) of 2330 U/L. Serology was reactive for HEV IgM (5.53 units), while other viral markers were negative. His bilirubin peaked at 60.1 mg/dL on day 4 of admission. He received supportive treatment and gradually improved. At 3 weeks post-discharge, his bilirubin had decreased to 5.4 mg/dL, and on follow-up, liver tests normalized and he was asymptomatic. Clinical discussion: This case illustrates an unusual but self-limiting course of HEV with marked hyperbilirubinemia. Early diagnosis is essential to distinguish it from more severe hepatic conditions, including acute drug-induced liver injury, autoimmune hepatitis flare, ischemic hepatitis, mushroom poisoning, and sepsis-associated cholestasis. Clear, compassionate communication is critical to reduce patient anxiety in the face of alarming lab values. Conclusion: Clinicians should consider HEV in patients presenting with acute hepatitis and extreme hyperbilirubinemia. Prompt diagnosis and patient reassurance are key to effective management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.